CN114945586A - 一种药物组合物及其用途 - Google Patents

一种药物组合物及其用途 Download PDF

Info

Publication number
CN114945586A
CN114945586A CN202180009111.7A CN202180009111A CN114945586A CN 114945586 A CN114945586 A CN 114945586A CN 202180009111 A CN202180009111 A CN 202180009111A CN 114945586 A CN114945586 A CN 114945586A
Authority
CN
China
Prior art keywords
polypeptide chain
seq
terminus
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180009111.7A
Other languages
English (en)
Inventor
张晋宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN114945586A publication Critical patent/CN114945586A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

本发明提供一种药物组合物，其包括蛋白质和免疫检查点抑制剂，其中所述蛋白质包括融合蛋白，且所述融合蛋白中包含细胞因子IL12、IL2和GMCSF。本发明还提供包括所述药物组合物的试剂盒以及所述药物组合物或所述试剂盒在制备用于治疗肿瘤的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (34)

  1. PCT国内申请，权利要求书已公开。
CN202180009111.7A 2020-01-21 2021-01-20 一种药物组合物及其用途 Pending CN114945586A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010071620X 2020-01-21
CN202010071620 2020-01-21
PCT/CN2021/072824 WO2021147886A1 (zh) 2020-01-21 2021-01-20 一种药物组合物及其用途

Publications (1)

Publication Number Publication Date
CN114945586A true CN114945586A (zh) 2022-08-26

Family

ID=76992078

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180009111.7A Pending CN114945586A (zh) 2020-01-21 2021-01-20 一种药物组合物及其用途

Country Status (3)

Country Link
US (1) US20230043257A1 (zh)
CN (1) CN114945586A (zh)
WO (1) WO2021147886A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112210014B (zh) * 2019-07-12 2022-10-11 北京科诺科服生物科技有限公司 一种用于治疗动物肿瘤的融合蛋白及组合物

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1374871A (zh) * 1999-07-21 2002-10-16 利思进药品公司 增强蛋白和肽抗原免疫原性的Fc融合蛋白
CN1382158A (zh) * 1999-08-09 2002-11-27 利思进药品公司 多细胞因子－抗体复合物
EP1731531A2 (en) * 1999-08-09 2006-12-13 EMD Lexigen Research Center Corp. Multiple cytokine-antibody complexes
CN103298935A (zh) * 2007-08-15 2013-09-11 阿穆尼克斯公司 用于改善生物活性多肽性能的组合物和方法
CN108463229A (zh) * 2016-01-11 2018-08-28 斯坦福大学托管董事会 嵌合蛋白和免疫治疗方法
CN108602872A (zh) * 2015-10-30 2018-09-28 艾丽塔生物治疗剂公司 用于治疗癌症的组合物和方法
WO2018184484A1 (zh) * 2017-04-06 2018-10-11 张晋宇 细胞因子组合
WO2018199595A1 (ko) * 2017-04-24 2018-11-01 주식회사 제넥신 4-1bbl 변이체 및 이를 포함하는 융합 단백질
WO2019067770A1 (en) * 2017-09-27 2019-04-04 Epicentrx, Inc. IMMUNOMODULATORY FUSION PROTEINS
WO2019129053A1 (zh) * 2017-12-26 2019-07-04 南京金斯瑞生物科技有限公司 以抗体Fc区为骨架的融合蛋白二聚体及其应用
WO2019144309A1 (en) * 2018-01-24 2019-08-01 Beijing Percans Oncology Co. Ltd. Cytokine Fusion Proteins
WO2019147837A2 (en) * 2018-01-24 2019-08-01 Beijing Percans Oncology Co. Ltd. Cytokine fusion proteins
WO2019185792A1 (en) * 2018-03-29 2019-10-03 Philogen S.P.A Cancer treatment using immunoconjugates and immune check-point inhibitors
CN111848811A (zh) * 2019-04-27 2020-10-30 张晋宇 一种蛋白质异二聚体及其用途
CN111848810A (zh) * 2019-04-28 2020-10-30 张晋宇 一种蛋白质分子及其用途
CN112513276A (zh) * 2018-07-30 2021-03-16 张晋宇 蛋白质异二聚体及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014139468A1 (en) * 2013-03-15 2014-09-18 Admark Healthcare, Llc Fusion protein molecules and method of use

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1374871A (zh) * 1999-07-21 2002-10-16 利思进药品公司 增强蛋白和肽抗原免疫原性的Fc融合蛋白
CN1382158A (zh) * 1999-08-09 2002-11-27 利思进药品公司 多细胞因子－抗体复合物
EP1731531A2 (en) * 1999-08-09 2006-12-13 EMD Lexigen Research Center Corp. Multiple cytokine-antibody complexes
CN103298935A (zh) * 2007-08-15 2013-09-11 阿穆尼克斯公司 用于改善生物活性多肽性能的组合物和方法
CN108602872A (zh) * 2015-10-30 2018-09-28 艾丽塔生物治疗剂公司 用于治疗癌症的组合物和方法
CN108463229A (zh) * 2016-01-11 2018-08-28 斯坦福大学托管董事会 嵌合蛋白和免疫治疗方法
WO2018184484A1 (zh) * 2017-04-06 2018-10-11 张晋宇 细胞因子组合
CN108686202A (zh) * 2017-04-06 2018-10-23 张晋宇 肿瘤免疫疗法
WO2018199595A1 (ko) * 2017-04-24 2018-11-01 주식회사 제넥신 4-1bbl 변이체 및 이를 포함하는 융합 단백질
CN111511769A (zh) * 2017-09-27 2020-08-07 埃皮辛特瑞柯斯公司 免疫调节性融合蛋白
WO2019067770A1 (en) * 2017-09-27 2019-04-04 Epicentrx, Inc. IMMUNOMODULATORY FUSION PROTEINS
WO2019129053A1 (zh) * 2017-12-26 2019-07-04 南京金斯瑞生物科技有限公司 以抗体Fc区为骨架的融合蛋白二聚体及其应用
CN111527109A (zh) * 2017-12-26 2020-08-11 南京金斯瑞生物科技有限公司 以抗体Fc区为骨架的融合蛋白二聚体及其应用
WO2019147837A2 (en) * 2018-01-24 2019-08-01 Beijing Percans Oncology Co. Ltd. Cytokine fusion proteins
WO2019144309A1 (en) * 2018-01-24 2019-08-01 Beijing Percans Oncology Co. Ltd. Cytokine Fusion Proteins
CN112105632A (zh) * 2018-01-24 2020-12-18 北京智康博药肿瘤医学研究有限公司 细胞因子融合蛋白
WO2019185792A1 (en) * 2018-03-29 2019-10-03 Philogen S.P.A Cancer treatment using immunoconjugates and immune check-point inhibitors
CN112513276A (zh) * 2018-07-30 2021-03-16 张晋宇 蛋白质异二聚体及其用途
CN111848811A (zh) * 2019-04-27 2020-10-30 张晋宇 一种蛋白质异二聚体及其用途
CN111848810A (zh) * 2019-04-28 2020-10-30 张晋宇 一种蛋白质分子及其用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
QIAN WEN 等: "Fusion cytokine IL-2-GMCSF enhances anticancer immune responses through promoting cell-cell interactions", 《JOURNAL OF TRANSLATIONAL MEDICINE》, vol. 14, no. 41, 5 February 2016 (2016-02-05) *
STEPHEN D. GILLIES等: "Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer", 《CANCER IMMUNOL IMMUNOTHER》, vol. 51, 12 July 2002 (2002-07-12), pages 1 - 2 *
刘冬梅等: "分泌型rhGM-CSF/IL-2融合蛋白表达载体的构建", 《中国生物制品学杂志》, no. 4, 31 December 2002 (2002-12-31), pages 197 - 200 *

Also Published As

Publication number Publication date
US20230043257A1 (en) 2023-02-09
WO2021147886A1 (zh) 2021-07-29

Similar Documents

Publication Publication Date Title
US11060097B2 (en) Immunotherapy methods using anti-PD-L1 antibodies in combination with EGFR1 targeted-TGF-beta immunomodulatory fusion proteins
CN109096396B (zh) 一种抗pd-l1人源化纳米抗体及其应用
JP7280827B2 (ja) Ａｘｌまたはｒｏｒ２に対するキメラ抗原受容体およびその使用方法
CN110818802B (zh) 一种嵌合t细胞受体star及其应用
WO2020017479A1 (ja) 抗ｇｐｃ３一本鎖抗体を含むｃａｒ
WO2020063787A1 (zh) 抗b7-h3的单克隆抗体及其在细胞治疗中的应用
KR20210021347A (ko) 다양한 다중 항원의 표적화를 위한 역방향 범용 키메라 항원 수용체 발현 면역 세포, 이의 제조 방법 및 암, 감염증 및 자가면역 장애의 치료를 위한 이의 용도
CN113234682B (zh) 靶向cd7的工程化免疫细胞、嵌合抗原受体、cd7阻断分子及应用
EA030147B1 (ru) Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
US20220356247A1 (en) ROR1 specific chimeric antigen receptors and their therapeutic applications
CN114144193A (zh) 一种液体制剂及其应用
CN110396129B (zh) 人源化cd19抗原结合单链抗体及其嵌合抗原受体、免疫细胞和应用
KR20200103708A (ko) 인간 메소텔린을 특이적으로 인식하는 세포 표면 분자, il-7, 및 ccl19 를 발현하는 면역 담당 세포
CN115867581A (zh) 含有保护肽的嵌合抗原受体及其用途
CN111944053B (zh) 抗bcma的car及其表达载体和应用
CN114945586A (zh) 一种药物组合物及其用途
JP2021517820A (ja) 抗ｃｄ３８及び抗ｃｄ１３８キメラ抗原受容体を含むｔ細胞、及びその用途
EP4299597A1 (en) Dual-target star targeting cd19 and cd22
JP7475088B2 (ja) ヒトメソセリンを特異的に認識する細胞表面分子、ｉｌ－７、及びｃｃｌ１９を発現する免疫担当細胞
KR102393776B1 (ko) Cd22에 특이적인 인간화 항체 및 이를 이용한 키메라 항원 수용체
WO2023088359A1 (zh) 靶向bcma的嵌合抗原受体及其应用
EP4159760A1 (en) Antibody specific to cd22, and use thereof
WO2023116637A1 (zh) 转基因免疫细胞及其构建方法和应用
KR20240034205A (ko) 항EGFRviii 항체, 폴리펩타이드, 상기 폴리펩타이드를 발현하는 세포, 상기 세포를 포함하는 의약 조성물, 상기 세포의 제조 방법 및 상기 폴리펩타이드를 코딩하는 염기서열을 포함하는 폴리뉴클레오티드 또는 벡터
KR20230058232A (ko) Cd138에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination